[Form 4] Moelis & Co Insider Trading Activity

Rhea-AI Filing Summary

Moelis & Co (MC) director Kenneth Shropshire reported receipt of restricted stock units on 09/18/2025. The Form 4 shows three dividend-equivalent RSU issuances tied to prior grants: 2024 Annual RSUs, 2025 Annual RSUs, and 2025 Elective RSUs. The filing lists numeric values associated with each line: 17.64 (2024 Annual), 14.72 (2025 Annual), and 1.74 (2025 Elective), and reports the amount of securities beneficially owned following the transactions as 2,127.9, 1,775.72, and 209.74 respectively. Shropshire is identified as a director and the Form 4 was signed by an attorney-in-fact, Osamu Watanabe, on 09/19/2025.

Positive

• Director received dividend-equivalent RSUs tied to prior awards, increasing reported beneficial ownership
• Vesting linkage disclosed: the dividend-equivalent RSUs will vest concurrently with the underlying Annual and Elective RSUs

Negative

• None.

Insights

Financial Analyst

TL;DR: Routine director compensation in the form of dividend-equivalent RSUs was reported; no cash sale or open-market trades are disclosed.

The Form 4 documents issuance of dividend-equivalent restricted stock units to Director Kenneth Shropshire on 09/18/2025 tied to prior Annual and Elective RSU awards. The filing lists post-transaction beneficial ownership amounts for each RSU line. There are no disclosed dispositions, option exercises, or open-market purchases in this filing, and no cash amounts or aggregate transaction prices are specified beyond the numeric entries shown on each line. For investors, this appears to be a compensation-related reporting event rather than a liquidity or market-trading event.

Corporate Governance Expert

TL;DR: This is a standard Section 16 disclosure of dividend-equivalent RSUs to a director; it documents increased beneficial ownership from compensation.

The report identifies Shropshire as a director and lists three separate RSU issuances described as dividend equivalents that will vest concurrently with the underlying awards. The filing was executed by an attorney-in-fact. The disclosure specifies the nature of the RSUs and the vesting linkage to underlying grants, indicating these are non-derivative, compensation-related equity awards rather than discretionary market transactions. No material governance concerns or departures are noted in this document alone.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Shropshire Kenneth

(Last) (First) (Middle)

399 PARK AVE

(Street)

NEW YORK NY 10022

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Moelis & Co [ MC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/18/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
2024 Annual Restricted Stock Units	09/18/2025		A		17.64	A	(1)(2)	2,127.9	D
2025 Annual Restricted Stock Units	09/18/2025		A		14.72	A	(1)(3)	1,775.72	D
2025 Elective Restricted Stock Units	09/18/2025		A		1.74	A	(1)(4)	209.74	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Each Restricted Stock Unit (RSU) represents the right to receive one share of Class A Common Stock.

2. 2024 Annual RSUs were issued as dividend equivalents on holder's underlying Annual RSUs issued on July 1, 2024. The dividend equivalent Annual RSUs will vest concurrently with the vesting of the underlying Annual RSUs.

3. 2025 Annual RSUs were issued as dividend equivalents on holder's underlying Annual RSUs issued on July 1, 2025. The dividend equivalent Annual RSUs will vest concurrently with the vesting of the underlying Annual RSUs.

4. 2025 Elective RSUs were issued as dividend equivalents on holder's underlying Elective RSUs issued on July 1, 2025. The dividend equivalent Elective RSUs will vest concurrently with the vesting of the underlying Elective RSUs.

	/s/ Osamu Watanabe as attorney-in-fact for Kenneth Shropshire	09/19/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Kenneth Shropshire report on the Form 4 for Moelis & Co (MC)?

The Form 4 reports receipt of dividend-equivalent restricted stock units (2024 Annual, 2025 Annual, and 2025 Elective RSUs) on 09/18/2025 and lists post-transaction beneficial ownership amounts.

How many RSUs were reported as beneficially owned after the transactions?

The filing lists post-transaction amounts as 2,127.9 (2024 Annual RSUs), 1,775.72 (2025 Annual RSUs), and 209.74 (2025 Elective RSUs).

Is Kenneth Shropshire an officer or director of Moelis & Co?

The Form 4 identifies Kenneth Shropshire as a Director of Moelis & Co.

Were any open-market purchases or sales disclosed in this Form 4?

No open-market purchases or sales are disclosed; the Form 4 shows issuances of dividend-equivalent RSUs, not market transactions.

Who signed the Form 4 for Kenneth Shropshire?

The Form 4 was signed by Osamu Watanabe as attorney-in-fact for Kenneth Shropshire on 09/19/2025.